What is Zacks Research’s Estimate for CL Q3 Earnings?

Colgate-Palmolive Company (NYSE:CL) – Equities researchers at Zacks Research lifted their Q3 2026 earnings per share estimates for shares of Colgate-Palmolive in a research report issued on Friday, August 14th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.92 for the quarter, up from their previous estimate of $0.91. The consensus estimate for Colgate-Palmolive’s current full-year earnings is $3.86 per share. Zacks Research also issued estimates for Colgate-Palmolive’s Q4 2026 earnings at $0.97 EPS, FY2026 earnings at $3.85 EPS, Q1 2027 earnings at $1.00 EPS, Q2 2027 earnings at $1.03 EPS, FY2027 earnings at $4.05 EPS and FY2028 earnings at $4.36 EPS.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, July 31st. The company reported $0.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.04. Colgate-Palmolive had a return on equity of 464.63% and a net margin of 9.68%.The business had revenue of $5.36 billion for the quarter, compared to analyst estimates of $5.36 billion. During the same period in the prior year, the company posted $0.92 EPS. The business’s revenue was up 4.9% compared to the same quarter last year.

A number of other research analysts also recently issued reports on CL. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $101.00 price target on shares of Colgate-Palmolive in a research report on Monday, August 3rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Colgate-Palmolive in a research report on Friday, July 31st. JPMorgan Chase & Co. dropped their price objective on shares of Colgate-Palmolive from $104.00 to $103.00 and set an “overweight” rating on the stock in a research note on Monday, August 3rd. Barclays raised their target price on shares of Colgate-Palmolive from $80.00 to $87.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 21st. Finally, Citigroup lifted their target price on Colgate-Palmolive from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Twelve equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $99.00.

Colgate-Palmolive Stock Performance

Colgate-Palmolive stock opened at $91.45 on Monday. The company has a debt-to-equity ratio of 13.82, a current ratio of 1.03 and a quick ratio of 0.67. Colgate-Palmolive has a 12 month low of $74.54 and a 12 month high of $99.33. The company has a fifty day moving average price of $91.83 and a two-hundred day moving average price of $90.10. The company has a market cap of $72.90 billion, a PE ratio of 36.29, a P/E/G ratio of 4.48 and a beta of 0.33.

Institutional Investors Weigh In On Colgate-Palmolive

Several large investors have recently made changes to their positions in CL. Kemnay Advisory Services Inc. bought a new position in Colgate-Palmolive in the 4th quarter worth approximately $25,000. CBIZ Investment Advisory Services LLC raised its stake in Colgate-Palmolive by 86.7% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 323 shares of the company’s stock valued at $26,000 after acquiring an additional 150 shares in the last quarter. TD Capital Management LLC raised its stake in Colgate-Palmolive by 61.4% during the 4th quarter. TD Capital Management LLC now owns 326 shares of the company’s stock valued at $26,000 after acquiring an additional 124 shares in the last quarter. Triumph Capital Management boosted its position in Colgate-Palmolive by 62.9% during the 4th quarter. Triumph Capital Management now owns 329 shares of the company’s stock worth $26,000 after acquiring an additional 127 shares during the period. Finally, Jessup Wealth Management Inc acquired a new position in Colgate-Palmolive during the 4th quarter worth $26,000. Institutional investors and hedge funds own 80.41% of the company’s stock.

Insider Buying and Selling at Colgate-Palmolive

In other news, CEO Noel R. Wallace sold 161,021 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $91.92, for a total transaction of $14,801,050.32. Following the completion of the transaction, the chief executive officer owned 362,231 shares in the company, valued at approximately $33,296,273.52. This represents a 30.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director John T. Cahill sold 4,170 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $93.37, for a total transaction of $389,352.90. Following the completion of the sale, the director directly owned 28,373 shares in the company, valued at approximately $2,649,187.01. This trade represents a 12.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.43% of the company’s stock.

Colgate-Palmolive Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Monday, July 20th were issued a dividend of $0.53 per share. The ex-dividend date of this dividend was Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.3%. Colgate-Palmolive’s payout ratio is 84.13%.

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.